Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial

The Lancet Respiratory Medicine

Volumn 7, Issue 11, 2019, Pages 941-950

  Beigel, John H ^a,l   Aga, Evgenia ^b,l   Elie Turenne, Marie Carmelle ^c,l   Cho, Josalyn ^d,l   Tebas, Pablo ^e,l   Clark, Carol L ^f,l   Metcalf, Jordan P ^g,l   Ozment, Caroline ^h,l   Raviprakash, Kanakatte ^i,l   Beeler, Joy ^j,l   Holley, H Preston ^j,l   Warner, Stephanie ^k,l   Chorley, Carla ^j,l   Lane, H Clifford ^a,l   Hughes, Michael D ^b,l   Davey, Richard T ^a,l   Barron, Michelle ^l   Bastani, Aveh ^l   Bauer, Philippe ^l   Borkowsky, William ^l   Cairns, Charles ^l   Deville, Jaime ^l   Fichtenbaum, Carl ^l   Finberg, Robert ^l   Jain, Mamta ^l   Kaufman, David ^l   Lin, Michael ^l   Lin, John ^l   Maves, Ryan ^l   Morrow, Lee ^l   Nguyen, Minh Hong ^l   Park, Pauline ^l   Polk, Christopher ^l   Randolph, Adrienne ^l   Rao, Suchitra ^l   Rubinson, Lewis ^l   Schofield, Christina ^l   Shoham, Shmuel ^l   Stalets, Erika ^l   Stapleton, Renee D ^l   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f Beaumont Hospital Royal   (United States)

^g UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ NAVAL MEDICAL RESEARCH CENTER   (United States)

^j FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^k SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIBODY;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALLERGIC REACTION; ANEMIA; ANTIBODY TITER; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEMAGGLUTINATION INHIBITION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA VACCINATION; INTENSIVE CARE UNIT; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATIONAL EARLY WARNING SCORE; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY DISTRESS; SCORING SYSTEM; TREATMENT RESPONSE; ADOLESCENT; BLOOD; CHILD; CLINICAL TRIAL; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS; MIDDLE AGED; PASSIVE IMMUNIZATION; PLASMA; PROCEDURES; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PLASMA; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85073502797     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(19)30199-7     Document Type: Article

References (26)

1. Lu J, Guo Z, Pan X, et al. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Respir Res 2006; 7: 43.
2. Hanson BJ, Boon ACM, Lim APC, Webb A, Ooi EE, Webby RJ. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 2006; 7: 126.
3. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145: 599–609.
4. Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52: 447–56.
5. Duggal A, Pinto R, Rubenfeld G, Fowler RA. Global variability in reported mortality for critical illness during the 2009–10 influenza A(H1N1) pandemic: a systematic review and meta-regression to guide reporting of outcomes during disease outbreaks. PLoS One 2016; 11: e0155044.
6. Beigel JH. Polyclonal and monoclonal antibodies for the treatment of influenza. Curr Opin Infect Dis 2018; 31: 527–34.
7. Beigel JH, Tebas P, Elie-Turenne MC, et al. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med 2017; 5: 500–11.
8. Royal College of Physicians. National early warning score (NEWS): standardising the assessment of acute-illness severity in the NHS. 2012. https://www.ombudsman.org.uk/sites/default/files/National%20Early%20Warning%20Score%20%28NEWS%29%20-%20Standardising%20the%20assessment%20of%20acute-illness%20severity%20in%20the%20NHS_0.pdf (accessed Dec 3, 2018).
9. Duncan H, Hutchison J, Parshuram CS. The Pediatric Early Warning System score: a severity of illness score to predict urgent medical need in hospitalized children. J Crit Care 2006; 21: 271–78.
10. Shu B, Wu KH, Emery S, et al. Design and performance of the CDC real-time reverse transcriptase PCR swine flu panel for detection of 2009 A (H1N1) pandemic influenza virus. J Clin Microbiol 2011; 49: 2614–19.
11. Centers for Disease Control and Prevention. Human influenza virus real-time RT-PCR detection and characterization panel. 2008. http://www.accessdata.fda.gov/cdrh_docs/pdf8/k080570.pdf (accessed Dec 26, 2018).
12. US Department of Health and Human Services. Guidance for Industry–influenza: developing drugs for treatment and/or prophylaxis. 2011. https://www.fda.gov/media/73339/download (accessed Aug 8, 2019).
13. WHO. Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva, Switzerland: World Health Organization, 2011.
14. Jones AE, Trzeciak S, Kline JA. The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. Crit Care Med 2009; 37: 1649–54.
15. Leteurtre S, Martinot A, Duhamel A, et al. Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre study. Lancet 2003; 362: 192–97.
16. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357: 1450–51.
17. Wu XX, Gao HN, Wu HB, Peng XM, Ou HL, Li LJ. Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma. Int J Infect Dis 2015; 41: 3–5.
18. US Food and Drug Administration. Benefit-Risk assessment in drug regulatory decision-making. 2018. https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM602885.pdf (accessed April 16, 2019).
19. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200: 492–500.
20. Lee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalised with severe influenza. Thorax 2010; 65: 510–15.
21. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55: 1198–204.
22. Hui DS, Lee N, Chan PK, Beigel JH. The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral Res 2018; 150: 202–16.
23. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70: 767–77.
24. Memoli MJ, Shaw PA, Han A, et al. Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A/H1N1 virus healthy human challenge model. MBio 2016; 7: e00417–16.
25. Davey RT Jr, Fernández-Cruz E, Markowitz N, et al. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet Respir Med 2019; published online Sept 30. https://doi.org/10.1016/S2213-2600(19)30253-X.
26. Beigel JH, Nam HH, Adams PL, et al. Advances in respiratory virus therapeutics–a meeting report from the 6th isirv Antiviral Group conference. Antiviral Res 2019; 167: 45–67.